Brief: aTyr Pharma Announces Dosing Of First Patient In Phase 2 Efzo-Connect Study Of Efzofitimod In Patients With Ssc-Ild
31/10/2023 12:03
Oct 31 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2
EFZO-CONNECT™ STUDY OF EFZOFITIMOD IN PATIENTS WITH SSC-ILD
Source text for Eikon: ID:nGNXbBlLh7
Further company coverage: LIFE.O
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan